Overview

A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

Status:
Completed
Trial end date:
2024-02-14
Target enrollment:
Participant gender:
Summary
The main aim of this study is to compare the amount of brigatinib in the blood of healthy adults after they have swallowed one dose either as a solution or as a tablet.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda